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Background: Phenotype of chronic rhinosinusitis (CRS) may be an important determining factor of the efficacy of
anti-inflammatory treatments. Although both glucocorticoids and macrolide antibiotics have been recommended
for the treatment of CRS, whether they have different anti-inflammatory functions for distinct phenotypic CRS has
not been completely understood. The aim of this study is to compare the anti-inflammatory effects of clarithromycin
and dexamethasone on sinonasal mucosal explants from different phenotypic CRS ex vivo.
Methods: Ethmoid mucosal tissues from CRSsNP patients (n = 15), and polyp tissues from eosinophilic (n = 13) and
non-eosinophilic (n = 12) CRSwNP patients were cultured in an ex vivo explant model with or without dexamethasone
or clarithromycin treatment for 24 h. After culture, the production and/or expression of anti-inflammatory molecules,
epithelial-derived cytokines, pro-inflammatory cytokines, T helper (Th)1, Th2 and Th17 cytokines, chemokines, dendritic
cell relevant markers, pattern recognition receptors (PRRs), and tissue remodeling factors were detected in tissue
explants or culture supernatants by RT-PCR or ELISA, respectively.
Results: We found that both clarithromycin and dexamethasone up-regulated the production of anti-inflammatory
mediators (Clara cell 10-kDa protein and interleukin (IL)-10), whereas down-regulated the production of Th2 response
and eosinophilia promoting molecules (thymic stromal lymphopoietin, IL-25, IL-33, CD80, CD86, OX40 ligand,
programmed cell death ligand 1, CCL17, CCL22, CCL11, CCL5, IL-5, IL-13, and eosinophilic cationic protein) and Th1
response and neutrophilia promoting molecules (CXCL8, CXCL5, CXCL10, CXCL9, interferon-γ, and IL-12), from sinonasal
mucosa from distinct phenotypic CRS. In contrast, they had no effect on IL-17A production. The expression of PRRs
(Toll-like receptors and melanoma differentiation-associated gene 5) was induced, and the production of tissue
remodeling factors (transforming growth factor-β1, epidermal growth factor, basic fibroblast growth factor, platelet
derived growth factor, vascular endothelial growth factor, and matrix metalloproteinase 9) was suppressed, in different
phenotypic CRS by dexamethasone and clarithromycin in comparable extent.
Conclusions: Out of our expectation, our explant model study discovered herein that glucocorticoids and macrolides
likely exerted similar regulatory actions on CRS and most of their effects did not vary by the phenotypes of CRS.
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Chronic rhinosinusitis (CRS) is a group of heterogeneous
inflammatory disorders of nose and the paranasal sinuses.
Based on the presence or absence of nasal polyps, CRS is
classified into CRS with nasal polyps (CRSwNP) and CRS
without nasal polyps (CRSsNP) [1]. Eosinophilic inflam-
mation has been considered to be a cardinal feature of
CRSwNP in whites for a long time. However, in Asians,
only half of CRSwNP present eosinophilic inflammation,
indicating a more heterogeneous feature of CRSwNP in
Asians [2, 3]. Although the etiology of CRS remains enig-
matic, all phenotypic CRS are characterized by prolonged
and persistent inflammation in the lesional sinonasal mu-
cosa [1, 2]. Therefore, the anti-inflammatory treatment is
currently considered as a primary treatment for CRS [1, 4].
Glucocorticoids have been widely used to control CRS
given their powerful and broad anti-inflammatory effects
[4, 5]. Glucocorticoids can suppress the chemotaxis and
activation of various immune cells including eosinophils,
T cells, and mast cells, etc. [5]. They can induce apop-
tosis of eosinophils and suppress the release of an array
of inflammatory cytokines, chemokines, and mediators
from resident and inflammatory cells in tissues [5]. Be-
yond the well-known antimicrobial effect, increasing evi-
dences have emerged to show that macrolides have
intrinsic anti-inflammation and immunomodulation prop-
erties [6, 7]. Macrolides can block the activation of
transcription factor nuclear factor κB and inhibit the pro-
duction of various inflammatory cytokines, including
interleukin (IL)-8 and tumor necrosis factor-α (TNF-α)
[6, 7]. They can also suppress the secretion of airway
mucus, induce the apoptosis of neutrophils, and even di-
minish the formation of bacterial biofilms [6, 7]. Some
studies have demonstrated the in vivo effect of long-time,
low-dose macrolide treatment on controlling CRS [1, 8–10].
Although glucocorticoids and macrolides have been
recommended for the treatment of CRS by European
Position Paper on Rhinosinusitis and Nasal Polyps [1],
there are a number of CRS patients that do not response
well to glucocorticoid treatment and conflicting results
exist regarding the efficacy of macrolide treatment in
CRS [1, 9, 10]. The reasons for the variations of efficacy
of glucocorticoids and macrolides are unclear, but part
of the problem is heterogeneity of CRS, with several
different pathways contributing to disease in different
patients. In whites, CRSsNP presents a predominant T
helper (Th) 1 milieu, whereas CRSwNP is characterized
by a Th2-skewed eosinophilic inflammation [3]. Never-
theless, in Chinese, only eosinophilic, but not non-
eosinophilic, CRSwNP demonstrates a Th2-dominated
inflammation [2, 11]. In addition, Th17 responses that
are almost absent in white patients with CRS have been
found up-regulated in Chinese [2, 3, 11–13]. Our recent
study has shown that although oral prednisone is able tosuppress the Th2-dominated eosinophilic inflammation,
it cannot inhibit the Th17 responses and associated neu-
trophilic inflammation in Chinese patients with CRSwNP
[14]. Wallwork et al. have found that macrolides may only
be efficient for CRSsNP patients without elevated serum
IgE levels [9]. We have found that long-term clarithromy-
cin treatment could inhibit IL-8 and myeloperoxidase
production in Chinese patients with CRSsNP and clari-
thromycin was more effective for CRSsNP patients with
high levels of IL-8 [15]. These studies suggest that the
phenotype of CRS might be a potential determining factor
of the efficacy of anti-inflammation agents, and glucocorti-
coids and macrolides might prefer to control eosinophilic
and neutrophilic inflammation, respectively. However, the
effects of glucocorticoids and macrolides on the inflamma-
tory responses in distinct phenotypic CRS have not been
carefully and comprehensively compared. Hence, in this
study we compared the effects of dexamethasone and clar-
ithromycin on different inflammatory pathways in sinona-
sal mucosa from Chinese patients with CRSsNP, and
eosinophilic and non-eosinophilic CRSwNP by using an
ex vivo tissue explant culture model.
Results
The pilot study of dose response effect of clarithromycin
and dexamethasone
In the pilot experiments, we found a concentration-
dependent effect of clarithromycin and dexamethasone
on the reduction of IL-8, and induction of IL-10 and
Clara cell 10-kD protein (CC10) production in sinonasal
mucosa from CRSsNP, and eosinophilic and non-
eosinophilic CRSwNP with a maximal response at a con-
centration of 10−5 mol/L (P < 0.05) (Fig. 1). In contrast,
we found that compared with controls, dexamethasone
and clarithromycin at serial concentrations of 10−7 mol/
L, 10−6 mol/L, and 10−5 mol/L did not have significant
influence on tissue cell viability after 24-h culture, and via-
bility of tissue cells from all CRS groups was >91 % in all
experiment conditions (Fig. 2). In order to confirm the spe-
cific effect of dexamethasone at a relatively high concentra-
tion of 10−5 mol/L, a glucocorticoid receptor antagonist,
mifepristone, was added to the culture. We discovered that
mifepristone could diminish the effect of 10−5 mol/L of
dexamethasone on IL-8, IL-10, and CC10 production in
sinonasal mucosa from all three CRS groups, confirming
the specific effect of dexamethasone (Fig. 3).
The effects of dexamethasone and clarithromycin on
epithelial-derived mediators
Our pilot experiments showed that 10−5 mol/L of dexa-
methasone and clarithromycin had maximal pharma-
ceutical effect without affecting the tissue cell viability.
In addition, this concentration was reported comparable
to that seen in serum during oral administration of
Fig. 1 The concentration-dependent effect of dexamethasone and clarithromycin on the production of interleukin (IL)-8, IL-10 and Clara cell
10-kD protein (CC10). Both of dexamethasone and clarithromycin demonstrated a significant concentration-dependent effect on the protein
production of (a-c) IL-8 and (d-f) IL-10 and (g-i) mRNA production of CC10 from sinonasal mucosa from different phenotypic chronic rhinosinusitis after
24-h culture (P < 0.05). Maximal effect was seen at a concentration of 10−5 mol/L. An equivalent volume of methanol solution was used as control for
dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis with
nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; CLA, clarithromycin; DEX, dexamethasone. n = 5 for CRSsNP, and Eos
and Non-Eos CRSwNP group
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when glucocorticoids are delivered intranasally, respect-
ively [16, 17]. Thus, we have chosen 10−5 mol/L as the
concentration for the following comparison experiment.
We found that dexamethasone and clarithromycin could
similarly up-regulate the mRNA expression of CC10
(Fig. 4a), whereas down-regulate the mRNA expression
of IL-25 (Fig. 4b), IL-33 (Fig. 4c), osteopontin (Fig. 4d)and thymic stromal lymphopoietin (TSLP) (Fig. 4e), in
sinonasal mucosa from CRSsNP, and eosinophilic and
non-eosinophilic CRSwNP patients.
The effects of dexamethasone and clarithromycin on
pro-inflammatory cytokines
Both dexamethasone and clarithromycin inhibited the
protein production of granulocyte-macrophage colony
Fig. 2 The tissue cell viability determined by trypan blue dye exclusion test. Dexamethasone and clarithromycin demonstrated no significant
influence on the viability of tissue cells from different phenotypic chronic rhinosinusitis at serial concentrations of 10−7 mol/L, 10−6 mol/L, and
10−5 mol/L, as compared to controls after 24-h tissue explant culture. An equivalent volume of methanol solution was used as control for
dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis
with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; CLA, clarithromycin; DEX, dexamethasone. n = 5 for CRSsNP,
and Eos and Non-Eos CRSwNP group
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from sinonasal mucosa from all three CRS groups in
similar extent. They could also suppress the protein pro-
duction of IL-1β (Fig. 5b) and tumor necrosis factor
(TNF)-α (Fig. 5d) from sinonasal mucosa from CRSsNP
and eosinophilic CRSwNP patients, but not from non-
eosinophilic CRSwNP patients.
The effect of dexamethasone and clarithromycin on
chemokines
Dexamethasone and clarithromycin suppressed the pro-
tein levels of CC chemokine ligand (CCL) 5/regulated
upon activation normal T cell expressed and secreted
(RANTES) (Fig. 6d) in culture supernatants, and mRNA
expression of CCL17/thymus and activation-regulated
chemokine (TARC) (Fig. 6e), CCL22/macrophage-derived
chemokine (MDC) (Fig. 6g), CXC chemokine ligandFig. 3 Glucocorticoid receptor antagonist, mifepristone, diminishes the effe
of dexamethasone (10−5 mol/L) on the reduction of (a) IL-8 protein, and th
mRNA production in the sinonasal mucosa from different phenotypic chro
solution was used as control for dexamethasone and clarithromycin. CRSsN
non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eos
DEX, dexamethasone; MIF, mifepristone. n = 5 for CRSsNP, and Eos and Non(CXCL) 5/epithelial neutrophil-activating peptide-78 (ENA-
78) (Fig. 6h) and CXCL9/monokine induced by interferon-
γ (MIG) (Fig. 6i) in sinonasal mucosa, from CRSsNP and
eosinophilic and non-eosinophilic CRSwNP patients in
similar extent. Clarithromycin and dexamethasone could
also similarly decrease the protein production of CXCL8/
IL-8 (Fig. 6a) from CRSsNP and non-eosinophilic CRSwNP
and CXCL10/interferon-γ-induced protein 10 (IP-10)
(Fig. 6b) and CCL11/eotaxin (Fig. 6c) from eosinophilic and
non-eosinophilic CRSwNP, and the mRNA expression of
CCL20/macrophage inflammatory protein-3α (MIP-3α)
(Fig. 6f) in CRSsNP and eosinophilic CRSwNP. In addition,
dexamethasone, but not clarithromycin, statistically signifi-
cantly down-regulated CXCL8/IL-8 protein levels (Fig. 6a)
in culture supernatants from eosinophilic CRSwNP,
CXCL10/IP-10 protein levels (Fig. 6b) in culture superna-
tants from CRSsNP, and mRNA expression levels ofct of dexamethasone. Mifepristone (10−5 mol/L) antagonized the effect
e promotion of (b) IL-10 protein and (c) Clara cell 10-kD protein (CC10)
nic rhinosinusitis after 24-h culture. An equivalent volume of methanol
P, chronic rhinosinusitis without nasal polyps; Non-Eos CRSwNP,
inophilic chronic rhinosinusitis with nasal polyps; CLA, clarithromycin;
-Eos CRSwNP group. *P < 0.05
Fig. 4 The effect of dexamethasone and clarithromycin on the expression of epithelial-derived mediators. The mRNA relative expression of
(a) Clara cell 10-kD protein (CC10), (b) interleukin (IL)-25, (c) IL-33, (d) osteopontin, and (e) thymic stromal lymphopoietin (TSLP) in the sinonasal
mucosa from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone or clarithromycin. An equivalent
volume of methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps;
Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps;
CLA, clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P < 0.05
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eosinophilic CRSwNP.
The effect of dexamethasone and clarithromycin on DC
relevant markers
Dexamethasone and clarithromycin could comparably
down-regulate the mRNA expression of CD86 (Fig. 7b)
and OX40 ligand (OX40L) (Fig. 7d) in sinonasal mucosa
from CRSsNP and eosinophilic CRSwNP patients, whereas
no statistically significant effect was observed for sinonasal
mucosa from non-eosinophilic CRSwNP patients. Both
dexamethasone and clarithromycin could down-regulate
the mRNA expression of CD80 (Fig. 7a), inducible costi-
mulator ligand (ICOSL) (Fig. 7c) and programmed cell
death ligand 1 (PD-L1) (Fig. 7e) in sinonasal mucosa from
all three CRS groups in similar extent.
The effect of dexamethasone and clarithromycin on Th
cytokines
After treatment with dexamethasone or clarithromycin,
we detected a remarkable and similar decrease of inter-
feron (IFN)-γ protein production (Fig. 8b) from sinonasal
mucosa from all CRS groups and IL-12 protein produc-
tion (Fig. 8e) from sinonasal mucosa from CRSsNP and
eosinophilic CRSwNP. Clarithromycin also suppressed IL-12 production (Fig. 8e) from sinonasal mucosa from non-
eosinophilic CRSwNP. Dexamethasone and clarithromy-
cin could significantly inhibit the protein production of
IL-5 (Fig. 8c) and IL-13 (Fig. 8f) in only eosinophilic polyp
tissues, possibly due to the very low expression levels of
IL-5 and IL-13 in CRSsNP and non-eosinophilic
CRSwNP. In contrast, neither dexamethasone nor clari-
thromycin had significant effect on IL-17A (Fig. 8g) pro-
tein production in CRS. In addition, both dexamethasone
and clarithromycin inhibited the mRNA expression of eo-
sinophilic cationic protein (ECP) (Fig. 8a) in sinonasal mu-
cosa from CRSsNP and eosinophilic CRSwNP, but not in
those from non-eosinophilic CRSwNP. On the contrary,
we observed a significantly and comparably up-regulated
production of IL-10 (Fig. 8d) protein from sinonasal mu-
cosa from all CRS groups after dexamethasone or clari-
thromycin treatment.
The effect of dexamethasone and clarithromycin on the
PRRs
Interestingly, we found that both dexamethasone and
clarithromycin were able to increase the mRNA expres-
sion of melanoma differentiation-associated gene 5
(MDA-5) (Fig. 9a), toll like receptor (TLR) 2 (Fig. 9b)
and TLR3 (Fig. 9c) in sinonasal mucosa from all CRS
Fig. 5 The effect of dexamethasone and clarithromycin on the production of pro-inflammatory cytokines. The protein levels of (a) granulocyte-
macrophage colony stimulating factor (GM-CSF), (b) interleukin (IL)-1β, (c) IL-6, and (d) tumor necrosis factor-α (TNF-α) in culture supernatants
from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone or clarithromycin. An equivalent volume of
methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos
CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; CLA,
clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P < 0.05
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tissues from eosinophilic and non-eosinophilic CRSwNP
patients in similar extent. Clarithromycin could up-
regulate the mRNA expression of TLR4 in sinonasal mu-
cosa from all CRS groups; while dexamethasone might
enhance the TLR4 expression in sinonasal mucosa from
CRSsNP and non-eosinophilic CRSwNP (Fig. 9d).
The effect of dexamethasone and clarithromycin on tissue
remodeling factors
The protein production of vascular endothelial growth
factor (VEGF) (Fig. 10a) and basic fibroblast growth factor
(FGF-basic) (Fig. 10b), and the mRNA production of epi-
dermal growth factor (EGF) (Fig. 10d) and matrix metallo-
proteinase 9 (MMP9) (Fig. 10e) from sinonasal mucosa
from all CRS groups could be down-regulated by dexa-
methasone and clarithromycin in similar extent. In
addition, both dexamethasone and clarithromycin was
able to similarly suppress the protein production of plate-
let derived growth factor-BB (PDGF-BB) (Fig. 10c) from
sinonasal mucosa from CRSsNP and eosinophilic
CRSwNP patients, and mRNA production of transforminggrowth factor-β1 (TGF-β1) (Fig. 10f) from sinonasal mu-
cosa from eosinophilic CRSwNP. Clarithromycin could
also down-regulate PDGF-BB (Fig. 10c) production in
non-eosinophilic CRSwNP, and dexamethasone was cap-
able to decrease TGF-β1 (Fig. 10f) production in CRSsNP.
Discussion
Development of phenotype-orientated therapeutic strat-
egies is critical for the improvement of CRS treatment.
Whether glucocorticoids and macrolides are more effect-
ive for specific phenotypic CRS has not been completely
understood. In this study, we have comprehensively com-
pared the efficacy of dexamethasone and clarithromycin
on the expression and/or production of epithelial-derived
mediators, anti- and pro-inflammatory cytokines, chemo-
kines, DC relevant markers, Th1/Th2/Th17 cytokines,
PRRs, and tissue remodeling factors in Chinese CRSsNP,
and eosinophilic and non-eosinophilic CRSwNP by using
a tissue explant culture model. To the best of our know-
ledge, this is the first study to carefully compare the anti-
inflammatory actions of glucocorticoids and macrolides in
the different phenotypic CRS. Overall, we are surprised to
Fig. 6 The effect of dexamethasone and clarithromycin on the production or expression of chemokines. The protein levels of (a) CXC chemokine
ligand (CXCL) 8/interleukin (IL)-8, (b) CXCL10/interferon-γ-induced protein 10 (IP-10), (c) CC chemokine ligand (CCL)11/eotaxin and (d) CCL5/
regulated upon activation normal T cell expressed and secreted (RANTES) in culture supernatants, and mRNA expression levels of (e) CCL17/
thymus and activation-regulated chemokine (TARC), (f) CCL20/macrophage inflammatory protein-3α (MIP-3α), (g) CCL22/macrophage-derived
chemokine (MDC), (h) CXCL5/epithelial neutrophil-activating peptide-78 (ENA-78) and (i) CXCL9/monokine induced by IFN-γ (MIG) in sinonasal
mucosa, from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone or clarithromycin. An equivalent
volume of methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps;
Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps;
CLA, clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P < 0.05
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lar anti-inflammation effects on different inflammatory
pathways in CRS and most of their effects did not vary by
the phenotypes of CRS in this tissue explant study.
CC10 and IL-10 are two important anti-inflammatory
molecules in airways. Our previous studies have shown
that CC10 and IL-10 production in sinonasal mucosa
can be induced by glucocorticoids [18, 19]. In this study,
we not only confirmed effect of dexamethasone whichvalidated our present experimental system, but also
demonstrated a similar effect of clarithromycin on CC10
and IL-10 induction in all phenotypic CRS, suggesting
both agents may exert their anti-inflammatory function
through promoting the production of anti-inflammatory
mediators.
“Epithelium-DC-Th cell” cross-talk and chemokines
play a key role in the formation of polarized Th response
and biased granulocyte activation in sinonasal mucosa.
Fig. 7 The effect of dexamethasone and clarithromycin on the expression of dendritic cell relevant markers. The mRNA expression of (a) CD80,
(b) CD86, (c) inducible costimulator ligand (ICOSL), (d) OX40 ligand (OX40L), and (e) programmed cell death ligand 1 (PD-L1) in sinonasal mucosa
from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone or clarithromycin. An equivalent volume of
methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos
CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; CLA,
clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P < 0.05
Fig. 8 The effect of dexamethasone and clarithromycin on production or expression of Th cytokines. The mRNA relative expression levels of
(a) eosinophilic cationic protein (ECP) in sinonasal mucosa, and the protein levels of (b) interferon (IFN)-γ, (c) interleukin (IL)-5, (d) IL-10, (e) IL-12,
(f) IL-13, and (g) IL-17A in culture supernatants, from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone
or clarithromycin. An equivalent volume of methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis
without nasal polyps; Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with
nasal polyps; CLA, clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P< 0.05
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Fig. 9 The effect of dexamethasone and clarithromycin on the expression of pattern recognition receptors. The mRNA expression levels of
(a) melanoma differentiation-associated gene-5 (MDA-5), (b) toll like receptor (TLR)2, (c) TLR3, (d) TLR4, and (e) TLR9 in the sinonasal mucosa from
different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/L of dexamethasone or clarithromycin. An equivalent volume of
methanol solution was used as control for dexamethasone and clarithromycin. CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos
CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; CLA,
clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for Eos and Non-Eos CRSwNP group. *P < 0.05
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licensing innate and adaptive immunity and promote
Th2 responses [20]. Our recent study has shown that
CD86+ activated myeloid and plasmacytoid DCs were in-
creased in both eosinophilic and non-eosinophilic
CRSwNP [11]. The OX40L/PD-L1+ lesional DCs likely
under the influence of TSLP in eosinophilic CRSwNP
can prime Th2 cells, whereas the low OX40L/PD-L1-ex-
pressing lesional DCs with a possible influence by osteo-
pontin in non-eosinophilic CRSwNP primarily induce
Th1/Th17 cells [11]. In this study, surprisingly, we found
that not only dexamethasone but also clarithromycin
was able to suppress the expression of TSLP, IL-25, IL-
33, CD80, CD86, OX40L, and PD-L1. Moreover, the
expression of Th2 cell and eosinophil chemokines, in-
cluding CCL17/TARC, CCL22/MDC, CCL11/eotaxin
and CCL5/RANTES, was also inhibited by both dexa-
methasone and clarithromycin. These changes were
coinciding with the down-regulation of Th2 cytokines
(IL-5 and IL-13) and ECP by both dexamethasone and
clarithromycin in eosinophilic polyp, indicating that be-
yond its well-known suppression on neutrophilic inflam-
mation [15, 21], macrolides may also possess an inhibitory
effect on the Th2-dominated eosinophilic inflammation asglucocorticoids. In fact, there are few previous reports
showing that macrolides treatment can reduce the ECP
levels in nasal secretion from CRS patients [21].
On the other hand, clarithromycin and dexamethasone
also demonstrated comparable action on ameliorating
neutrophilic inflammation through diminishing the ex-
pression of neutrophil chemokines (e.g., CXCL8/IL-8
and CXCL5/ENA-78) in CRS. Moreover, both clarithro-
mycin and dexamethasone suppressed Th1 responses
by decreasing the expression of Th1 cell chemokines
(CXCL10/IP-10 and CXCL9/MIG) and Th1 cytokines
(IFN-γ and IL-12), but had no effect on IL-17A produc-
tion, in all phenotypic CRS. Consistently, our previous
in vivo study has showed that oral prednisone treatment
could not suppress Th17 response in Chinese CRSwNP
[14]. Thus, these studies arouse the need to seeking novel
therapies targeting Th17 responses in CRS.
Pro-inflammatory cytokines act as intercellular signals
to regulate the functions of DCs and other immune
cells. In this study, we found that GM-CSF, IL-6, TNF-α
and IL-1β production could be diminished by dexa-
methasone and clarithromycin, which is consistent with
previous reports and in line with their inhibitory effect
on NF-κB signaling pathway [5, 17, 22, 23].
Fig. 10 The effect of dexamethasone and clarithromycin on the expression or production of tissue remodeling factors. The protein levels of
(a) vascular endothelial growth factor (VEGF), (b) basic fibroblast growth factor (FGF-basic) and (c) platelet derived growth factor-BB (PDGF-BB) in
culture supernatants, and the mRNA relative expression levels of (d) epidermal growth factor (EGF), (e) matrix metalloproteinases 9 (MMP9) and
(f) transforming growth factor-β1 (TGF-β1) in sinonasal mucosa, from different phenotypic chronic rhinosinusitis after 24-h culture with 10−5 mol/
L of dexamethasone or clarithromycin. An equivalent volume of methanol solution was used as control for dexamethasone and clarithromycin.
CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos CRSwNP, non-eosinophilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP,
eosinophilic chronic rhinosinusitis with nasal polyps; CLA, clarithromycin; CON, control; DEX, dexamethasone. n = 5 for CRSsNP group; n = 6 for
Eos and Non-Eos CRSwNP group. *P < 0.05
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that although glucocorticoids could inhibit acute phase
response in airway epithelial cells, it may spare or enhance
the expression of local innate host defense molecules,
such as complements, collectins, and other antimicrobial
proteins [24]. In addition, Homma et al. have found that
dexamethasone synergistically increased TLR2 expression
in respiratory epithelial cells in combination with TNF-α
and IFN-γ [25]. PRRs are crucial in recognizing a wide
range of microbial pathogens and triggering signaling cas-
cades that activate effective immune responses. In line
with Zhang’s and Homma’s reports [24, 25], interestingly,
we found herein that although glucocorticoids and macro-
lides were able to diminish the expression of an array of
inflammatory molecules, they did increase the expression
of TLRs and MDA-5 in sinonasal mucosa from CRS.
These data suggest that glucocorticoids and macrolides
may reinforce the local innate host defense against infec-
tious organisms in airways and therefore reduce the ex-
acerbation of CRS.
Besides the persistent inflammation, the sinonasal mu-
cosa of CRS patients is also characterized by marked tis-
sue remodeling [26, 27]. Our previous study demonstrateddistinct remodeling features of different phenotypic CRS in
Chinese [26]. Eosinophilic CRSwNP shows marked
edema; on the contrary, CRSsNP presents significant fi-
brosis [26, 27]. This remodeling process may be controlled
by growth factor-induced extracellular matrix deposition
and proteases-dominated degradation [26–29]. Extending
previous findings on dexamethasone [30–32], we found
herein that both dexamethasone and clarithromycin might
suppress the remodeling process in CRS through sup-
pressing the expression of remodeling relevant mediators.
We have to acknowledge several limitations of our
current study that ask us to explain our results with cau-
tion. The most important one is that although we used
tissue explant culture to simulate in vivo condition as
closely as possible, whether these two agents can exert
same efficacy in vivo needs further study. Secondly, we
treated tissue samples for 24-h that is significant differ-
ent from the time period of treatment we used in clinic.
Thirdly, we did not do the dose–response experiments
for all studied parameters given the limited amount of
tissue samples. Moreover, it should be noted that our
current study is a small sample size study and further con-
firmation with a larger population is needed. Fourthly,
Zeng et al. BMC Immunology  (2015) 16:37 Page 11 of 15although the concentration of 10−5 mol/L we used in tis-
sue explant culture is close to the concentration achiev-
able in patients and both drugs at this concentration did
not reduce the tissue cell viability, we still need to explain
our data with caution since this concentration, especially
for dexamethasone, is much higher than that commonly
used in cell culture study. Fifthly, for some molecules, we
only measured the mRNA expression levels because of the
limited amount of tissue samples, therefore the changes of
these molecules at protein level wait to be confirmed in
future. Sixthly, although we found the changes of the ex-
pression and/or production of these molecules in CRS,
the intracellular and intercellular mechanisms underlying
the actions of dexamethasone and clarithromycin remain
to be defined in future.
Conclusions
In conclusion, our ex vivo results likely reflect the simi-
lar efficacy of glucocorticoids and macrolides to regulate
different patterns of inflammation response, innate im-
munity, and tissue remodeling in CRS and their effects
did not vary by the phenotypes of CRS. Our results pro-
vide the possibility of using dexamethasone and clari-
thromycin to reduce the exacerbation of CRS and
employing clarithromycin to treat eosinophilic inflam-
mation in CRS as a steroid sparing drug. At same time,
our study arouses the need to develop novel therapies
targeting Th17 responses in CRS. However, obviously,
further in vivo studies are needed to clarify the efficacy
of dexamethasone and clarithromycin on the treatment
of different phenotypic CRS. Moreover, whether there is
a synergetic effect between dexamethasone and clari-




In the pilot dose response, cell viability, and dexametha-
sone receptor blocking study, 10 patients with CRSsNP,
6 patients with non-eosinophilic CRSwNP, and 7Table 1 Clinical data of patients enrolled in pilot and further compa
Pilot study
CRSsNP Non-Eos CRSwNP
Subject, n 10 6
Gender, male, n (%) 6 (60 %) 4 (66.7 %)
Age (years), median (IQR) 38 (30–47.5) 39 (36.5-52)
Patients with atopy, n (%) 2 (20 %) 0 (0)
Patients with AR, n (%) 0 (0) 0 (0)
Patients with asthma, n (%) 0 (0) 0 (0)
CRSsNP, chronic rhinosinusitis without nasal polyps; Non-Eos CRSwNP, non-eosinop
rhinosinusitis with nasal polyps; IQR, inter-quartile range; AR, allergic rhinitispatients with eosinophilic CRSwNP were recruited. In
the further comparison study of dexamethasone and
clarithromycin, 5 patients with CRSsNP, 6 patients with
non-eosinophilic CRSwNP and 6 patients with eosino-
philic CRSwNP were enrolled. The detailed clinical data
of patients are summarized in Table 1. Diseased ethmoid
sinus mucosal tissues and polyp tissues were collected
during surgery from CRSsNP and CRSwNP patients, re-
spectively. The diagnosis of CRS was made according to
the European Position Paper on Rhinosinusitis and
Nasal Polyps [1]. CRSwNP was classified as eosinophilic
when percent tissue eosinophils exceeded 10 % of total
infiltrating cells as defined by our previous study based
on the evaluation of hematoxylin-eosin stained tissue
sections [2]. Atopic status was determined using skin
prick test with a standard panel of 20 inhalant allergens
common in our region [33]. The diagnosis of allergic
rhinitis was based on the concordance between a typical
history of allergic symptoms and the skin prick test re-
sults. The diagnosis of asthma was made according to
Global Initiative for Asthma 2006 guideline [34]. Oral
glucocorticoid and intranasal steroid spray were discon-
tinued at least 3 months and 1 month before surgery,
respectively. The patients who had an acute upper re-
spiratory infection in the 4 weeks before the surgery
were excluded in this study. None of subjects had an
antrochoanal polyps, cystic fibrosis, primary ciliary dys-
kinesia, fungal sinusitis, gastroesophageal reflux diseases,
aspirin sensitivity, or previous sinus surgery. This study
was approved by the Ethics Committee of Tongji Hos-
pital of Tongji Medical College of Huazhong University
of Science and Technology and conducted with written
informed consents from all participants.
Nasal tissue explant culture
Sinonasal mucosal samples were used for ex vivo air-
liquid interface culture as described previously [35].
Briefly, the ethmoid mucosa or polyp tissues were sec-
tioned into multiple samples of approximately 6 mm3
and sections of tissues were placed on 0.4-μm wellrison studies
Further comparison study
Eos CRSwNP CRSsNP Non-Eos CRSwNP Eos CRSwNP
7 5 6 6
3 (42.9 %) 3 (60 %) 5 (83.3 %) 4 (66.7 %)
35 (26–43.5) 46 (27–49) 35.5 (30.25-41.5) 43 (36.75-53)
1 (14.3 %) 0 (0) 0 (0) 0 (0)
1 (14.3 %) 0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0) 0 (0)
hilic chronic rhinosinusitis with nasal polyps; Eos CRSwNP, eosinophilic chronic
Table 2 Primers used for quantitative polymerase chain reaction assay
Primer Sequence Annealing temperature (°C) Expected product size (bp)
CC10 [S] 5'-GGACACACCCTCCAGTTATGA-3' 60 126
[A] 5'-ATGATGCTTTCTCTGGGCTTT-3'
IL-33 [S] 5'-ACAGCAAAGTGGAAGAACACAG-3' 60 162
[A] 5'-CCTTTTGGTGGTTTCTCTCCTA-3'
TSLP [S] 5’-CCCAGGCTATTCGGAAACTCA-3’ 60 118
[A] 5'-ACGCCACAATCCTTGTAATTGTG-3'
IL-25 [S] 5'-AAGGAGATGGTTGGTCAGAAGA-3' 58 182
[A] 5'-CTCCTAATCGCAAAAGAGCATC-3'
Osteopontin [S] 5'-CAACCGAAGTTTTCACTCCAG-3' 58 173
[A] 5'-ATTCAACTCCTCGCTTTCCAT-3'
CCL20/MIP-3α [S] 5'-GAATCAGAAGCAGCAAGCAAC-3' 60 209
[A] 5'-TTTTTACTGAGGAGACGCACAA-3'
CXCL19/MIG [S] 5'-GTTCTTTTCCTCTTGGGCATC-3' 60 108
[A] 5'-GATAGTCCCTTGGTTGGTGCT-3'
CCL17/TARC [S] 5'-GCCCCACTGAAGATGCTG-3' 60 204
[A] 5'-GCCCTGCACAGTTACAAAAAC-3'
CCL22/MDC [S] 5'-TGATTACGTCCGTTACCGTCT-3' 60 179
[A] 5'-AGTAGGCTCTTCATTGGCTCA-3'
CXCL5/ENA-78 [S] 5'-TTACAGACCACGCAAGGAGTT-3' 60 105
[A] 5'-GTTCTTCAGGGAGGCTACCAC-3'
ECP [S] 5'-TGCCCTCATAACAGAACTCTCA-3' 60 216
[A] 5'-GATGGTGGTATCCAGGTGAACT-3'
MDA-5 [S] 5'-GTTTGGCAGAAGGAAGTGTCA-3' 60 213
[A] 5'-CTGTAGGGAGGCAGATGATGA-3'
TLR2 [S] 5'-ATGCTGCCATTCTCATTCTTCT-3' 60 101
[A] 5'-CTCCAGGTAGGTCTTGGTGTTC-3'
TLR3 [S]5'-CGCTAAAAAGTGAAGAACTGGA-3' 60 100
[A]5'-TGAAAACACCCTGGAGAAAACT-3'
TLR4 [S] 5'-CTTCTCAACCAAGAACCTGGAC-3' 60 158
[A] 5'-TAGAGAGGTGGCTTAGGCTCTG-3'
TLR9 [S] 5'-CTACAACCGCATCGTCAAACT-3' 60 217
[A] 5'-ATTCAGCCAGGAGAGAGAACTG-3'
EGF [S] 5'-CTCATCACTGGTTGTGGTTCAT-3' 60 133
[A] 5'-CATAAAACCTTCACGACACGAA-3'
MMP9 [S] 5'-ACCACCACAACATCACCTATTG-3' 60 166
[A] 5'-ACACCAAACTGGATGACGATG-3'
TGF-β1 [S] 5'-CAGCAACAATTCCTGGCGATA-3' 57 136
[A] 5'-AAGGCGAAAGCCCTCAATTT-3'
CD86 [S] 5'-CAGCCTCTTCTTCTCTCAGCAG-3' 60 100
[A] 5'-CTCACTGGGGTCTGTGGTCT-3'
OX40L [S] 5'-AAATGAAGAGGAGCAAGGAGTG-3' 60 247
[A] 5'-CTGGGAAAGCAAAATGGTAAAG-3'
ICOSL [S] 5'-AGGTTTTGAGCGTTGAGGTTAC-3' 60 165
[A] 5'-GGCTGTTGTCCGTCTTATTGAT-3'
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Table 2 Primers used for quantitative polymerase chain reaction assay (Continued)
PD-L1 [S] 5'-GAACTACCTCTGGCACATCCTC-3' 60 126
[A] 5'-CACATCCATCATTCTCCCTTTT-3'
CD80 [S] 5'-TAATAAGCAAAGGGAGCACTGG-3' 60 140
[A] 5'-GCACAGGAGTCTGATGAACAAA-3'
GAPDH [S] 5'-ACCCAGAAGACTGTGGATGG-3' 61 201
[A] 5'-TTCTAGACGGCAGGTCAGGT-3'
CC10, Clara cell 10-kD protein; IL, interleukin; TSLP, thymic stromal lymphopoietin; CCL, CC chemokine ligand; MIP-3α, macrophage inflammatory protein-3α; CXCL,
CXC chemokine ligand; MIG, monokine induced by interferon-γ; TARC, thymus and activation-regulated chemokine; MDC, macrophage-derived chemokine;
ENA-78, epithelial neutrophil-activating peptide-78; ECP, eosinophilic cationic protein; MDA-5, melanoma differentiation-associated gene 5; TLR, Toll-like receptor;
EGF, epidermal growth factor; MMP9, matrix metalloproteinase 9; TGF-β1, transforming growth factor-β1; OX40L, OX40 ligand; ICOSL, inducible costimulator ligand;
PD-L1, programmed cell death ligand 1; GAPDH, glyceraldehydes-3-phosphate dehydrogenase




GM-CSF 8 NeoBioscience Technology Co
(Shenzhen, China)
IL-6 0.5 NeoBioscience Technology Co
TNF-α 8 NeoBioscience Technology Co
IL-1β 4 Shanghai Excell Biology, Inc
(Shanghai, China)
IFN-γ 0.2 NeoBioscience Technology Co
IL-12 4 eBioscience (San Diego, CA, USA)
IL-4 3.9 Shanghai Excell Biology, Inc
IL-5 2 Shanghai Excell Biology, Inc
IL-13 0.7 eBioscience
IL-17A 0.23 eBioscience
IL-10 0.5 NeoBioscience Technology Co
CXCL10/IP-10 8 NeoBioscience Technology Co
CCL11/eotaxin 1.4 eBioscience
CCL5/RANTES 7 Shanghai Excell Biology, Inc
CXCL8/IL-8 2 eBioscience
VEGF 8 NeoBioscience Technology Co
FGF-basic 7 Shanghai Excell Biology, Inc
PDGF-BB 4.6 eBioscience
GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin;
TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; CXCL, CXC chemokine
ligand; IP-10, interferon-γ-induced protein 10; CCL, CC chemokine ligand;
RANTES, regulated upon activation normal T cell expressed and secreted;
VEGF, vascular endothelial growth factor; FGF-basic, basic fibroblast growth
factor; PDGF-BB, platelet derived growth factor-BB
Zeng et al. BMC Immunology  (2015) 16:37 Page 13 of 15inserts (Millipore Corp., Billerica, MA, USA) in 2 mL of
Dulbecco’s modified Eagle’s medium/F-12 supplemented
with 2 mM glutamine, 100 U/mL penicillin, and 100 μg/
mL streptomycin (Invitrogen, Carlsbad, CA, USA) [35, 36].
The tissue samples were oriented with the epithelium
being exposed to the air, forming an air-liquid interface
to mimic the in vivo situation. The tissues were cultured
at 37 °C with 5 % CO2 in humidified air. In the pilot
dose response and cell viability study, tissues were
cultured with dexamethasone or clarithromycin (Sigma,
St. Louis, MO, USA) for 24 h, at serial concentrations of
10−7 mol/L, 10−6 mol/L, and 10−5 mol/L. In some exper-
iments with 10−5 mol/L of dexamethasone, a gluco-
corticoid receptor antagonist, mifepristone (10−5 mol/L;
USBiological, Swampscott, MA, USA), was added to
confirm the specific effect of dexamethasone. Based on
the results of pilot experiments, in the further compari-
son study of dexamethasone and clarithromycin, tissues
were treated with 10−5 mol/L of dexamethasone or clar-
ithromycin for 24 h. This concentration was reported
comparable to that seen in serum during oral adminis-
tration of clarithromycin, and was close to local concen-
tration when glucocorticoids are delivered intranasally,
respectively [16, 17]. In tissue explant culture, an equiva-
lent volume of diluent, methanol solution (Sigma) was
used as control. After culture, the culture supernatants
and tissues were collected and stored at −80 °C for subse-
quent ELISA and quantitative real-time polymerase chain
reaction (PCR) analysis, respectively; or the tissues were
subject to cell viability assessment immediately.
Cell viability assessment
After culture, tissues were harvested and dissociated
mechanically with the GentleMACS Dissociator (Miltenyi
Biotec Technology & Trading (Shanghai) Co. Shanghai,
China) immediately [37]. Then the single cell suspension
was generated and the cell viability was estimated by try-
pan blue (Sigma) dye exclusion test. At least 600 cells
were counted in four different fields and the number of
viable cells was calculated as a percentage of total cell
population [38].Quantitative real-time polymerase chain reaction
Total RNA was extracted from tissue samples by using
TRI reagent (Invitrogen) and treated by using a DNA-free
kit (Fermentas, Hanover, MD, USA) to remove contamin-
ating DNA. One microgram total RNA was reverse-
transcribed to cDNA with random hexamer primer as
previously described [35, 39]. cDNA equivalent to 40 ng
total RNA was used to perform quantitative real-time
PCR by using the SYBR Premix Ex Taq kit (TaKaRa Bio-
technology, Dalian, China) with appropriate primers as
Zeng et al. BMC Immunology  (2015) 16:37 Page 14 of 15mentioned elsewhere [35, 39]. The following targets were
detected, including epithelial-derived mediators, chemo-
kines, pattern recognition receptors (PRRs), tissue remod-
eling factors, and dendritic cell (DC) markers. The list of
genes detected and the corresponding primers are shown
in Table 2. Relative gene expression was calculated by using
the comparative CT method [35, 39]. Glyceraldehydes-3-
phosphate dehydrogenase was used as a housekeeping
gene for normalization, and a sample from control group
was served as a calibrator. A no template sample was
employed as a negative control for PCR assay.
ELISA
The protein levels in culture supernatants were mea-
sured by using commercial ELISA kits according to the
manufacturer’s recommendations. The detected proteins
included pro-inflammatory cytokines, Th1/Th2/Th17 cy-
tokines, chemokines, and tissue remodeling factors. The
list of proteins detected and the corresponding detection
limits are shown in Table 3.
Statistical analysis
The data are expressed as median and inter-quartile
range or in box plots that represent medians and inter-
quartile ranges. Repeated-measures analysis of variance
was used to determine a concentration-dependent drug
effect on cytokine production and cell viability. The
Kruskal-Wallis H test was used to assess significant in-
tergroup variability and the Mann–Whitney U 2-tailed
test was used for between-group comparisons. Signifi-
cance was accepted at P < 0.05.
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